Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Barlesi, Fabrice; Vansteenkiste, Johan; Spigel, David; Ishii, Hidenobu; Garassino, Marina; de Marinis, Filippo; Ozguroglu, MUSTAFA; Szczesna, Aleksandra; Polychronis, Andreas; Uslu, Ruchan; Krzakowski, Maciej; Lee, Jong-Seok; Calabro, Luana; Frontera, Osvaldo; Ellers-Lenz, Barbara; Bajars, Marcis; Ruisi, Mary; Park, Keunchil

doi:10.1016/s1470-2045(18)30673-9

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Barlesi F., Vansteenkiste J., Spigel D., Ishii H., Garassino M., de Marinis F., ...Daha Fazla

LANCET ONCOLOGY, cilt.19, sa.11, ss.1468-1479, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 19 Sayı: 11
Basım Tarihi: 2018
Doi Numarası: 10.1016/s1470-2045(18)30673-9
Dergi Adı: LANCET ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1468-1479
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.